Published in J Virol on April 01, 2003
Evaluation of Long Term Immunity Following HPV Vaccination | NCT02276521
Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol (2004) 1.27
Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J Virol (2006) 1.06
DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants. Genet Vaccines Ther (2008) 1.03
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol (2009) 1.02
Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J Virol (2005) 1.00
Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Invest Dermatol (2013) 0.97
Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. J Virol (2009) 0.89
Plant-produced cottontail rabbit papillomavirus L1 protein protects against tumor challenge: a proof-of-concept study. Clin Vaccine Immunol (2006) 0.87
Monitoring of vaccine-specific gamma interferon induction in genital mucosa of mice by real-time reverse transcription-PCR. Clin Vaccine Immunol (2008) 0.84
Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization. Viral Immunol (2009) 0.83
Titanium salan complexes displays strong antitumor properties in vitro and in vivo in mice. PLoS One (2011) 0.83
Virus-based nanoparticles as platform technologies for modern vaccines. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.80
New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention. Antivir Ther (2011) 0.79
Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice. Med Microbiol Immunol (2014) 0.78
Advanced antigen delivery of murine survivin: chimeric virus-like particles in cancer vaccine research. Int J Biomed Sci (2007) 0.76
Characterization of two new monoclonal antibodies against human papillomavirus type 16 L1 protein. Diagn Pathol (2014) 0.75
Observations on the expression of human papillomavirus major capsid protein in HeLa cells. Cancer Cell Int (2015) 0.75
C3-Luc Cells Are an Excellent Model for Evaluation of Cellular Immunity following HPV16L1 Vaccination. PLoS One (2016) 0.75
SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics (1999) 14.15
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58
Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer (1999) 8.61
Fine specificity analysis with monoclonal antibodies of antigens controlled by the major histocompatibility complex and by the Qa/TL region in mice. Immunol Rev (1979) 4.31
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A (1995) 4.15
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14
Clottable protein in Limulus; its localization and kinetics of its coagulation by endotoxin. Thromb Diath Haemorrh (1968) 3.90
Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med (1985) 3.86
Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol (1993) 3.73
Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell (2000) 3.44
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28
Recognition of gram-negative bacteria and endotoxin by the innate immune system. Curr Opin Immunol (1999) 2.85
Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol (2001) 2.28
A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods (2001) 2.15
HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods (2002) 1.97
Gene expressions of Toll-like receptor 2, but not Toll-like receptor 4, is induced by LPS and inflammatory cytokines in mouse macrophages. J Immunol (2000) 1.86
Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. J Virol (1998) 1.67
Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci U S A (1998) 1.59
Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. J Virol (1997) 1.58
Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol (2001) 1.55
Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol (1998) 1.49
Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol (1998) 1.48
Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. J Mol Biol (2001) 1.46
Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J Immunol (2001) 1.39
NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology (2001) 1.34
Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies. Virology (2000) 1.31
HPV innate immunity. Front Biosci (2002) 1.21
Chimeric papillomavirus-like particles. Virology (1997) 1.17
Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies. Vaccine (2001) 1.15
L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology (1998) 1.15
Human papillomavirus vaccines. Semin Cancer Biol (1999) 1.13
Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Biotechniques (2000) 1.13
Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33. Virology (2001) 1.00
Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. J Infect Dis (2001) 0.99
Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer (1999) 0.97
Cervical cancer vaccines: emerging concepts and developments. J Cell Physiol (2001) 0.92
Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions. J Clin Microbiol (2002) 0.91
Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch Med Res (2000) 0.90
Calcium is required in reassembly of bovine papillomavirus in vitro. J Gen Virol (1998) 0.88
Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J Cell Biochem (1999) 0.88
Monoclonal antibody against a cross-reactive idiotypic determinant found on human autoantibodies with anti-I and -i specificities. Mol Immunol (1983) 0.87
Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses. Immunol Cell Biol (2002) 0.86
Expression of human papillomavirus type 16 L1 protein in Escherichia coli: denaturation, renaturation, and self-assembly of virus-like particles in vitro. Virology (1998) 0.86
T cell response to human papillomavirus 16 E7 in mice: comparison of Cr release assay, intracellular IFN-gamma production, ELISPOT and tetramer staining. Intervirology (2002) 0.84
Removal of endotoxin from culture media by a polymyxin B sepharose column. The activity of contaminating endotoxin in culture media measured by the interleukin 1 inducing effect on human monocyte cultures and by the Limulus test. Scand J Immunol (1987) 0.83
Therapeutic vaccines for human papillomaviruses. Intervirology (2001) 0.82
The role of human papillomavirus vaccines in cervical neoplasia. Best Pract Res Clin Obstet Gynaecol (2001) 0.78
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol (2005) 7.94
Chapter 1: HPV in the etiology of human cancer. Vaccine (2006) 6.61
Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst (2003) 6.28
Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) (2009) 6.12
Seroepidemiology of human polyomaviruses. PLoS Pathog (2009) 4.62
The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat Struct Mol Biol (2008) 4.33
A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29
Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem (2005) 4.18
IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol (2003) 3.69
Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst (2003) 3.44
Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol (2006) 3.13
Cell-wall recovery after irreversible deformation of wood. Nat Mater (2003) 3.09
Suppression of non-specific binding in serological Luminex assays. J Immunol Methods (2005) 2.96
Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol (2013) 2.87
Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog (2006) 2.65
Subunit interactions in bovine papillomavirus. Proc Natl Acad Sci U S A (2010) 2.51
JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol (2007) 2.44
Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst (2006) 2.40
Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol (2003) 2.14
Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J Exp Med (2009) 2.10
A cornucopia of human polyomaviruses. Nat Rev Microbiol (2013) 2.08
Taxonomical developments in the family Polyomaviridae. Arch Virol (2011) 2.03
Helicobacter pylori protein-specific antibodies and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev (2013) 2.01
HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods (2002) 1.97
Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog (2009) 1.92
Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol (2008) 1.90
Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A (2011) 1.89
E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS Pathog (2011) 1.89
Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci U S A (2002) 1.85
Oxidation-responsive polymeric vesicles. Nat Mater (2004) 1.82
Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem (2007) 1.77
Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res (2012) 1.76
TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol (2007) 1.70
Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol (2002) 1.67
IL-17-induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs. J Exp Med (2014) 1.67
Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein. J Biol Chem (2008) 1.61
RIM-binding protein, a central part of the active zone, is essential for neurotransmitter release. Science (2011) 1.59
Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol (2004) 1.58
High-risk HPV types and head and neck cancer. Int J Cancer (2014) 1.56
Chaperone-mediated in vitro assembly of Polyomavirus capsids. Proc Natl Acad Sci U S A (2003) 1.56
Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients. Gynecol Oncol (2002) 1.56
Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int J Epidemiol (2011) 1.55
Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol (2009) 1.55
Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res (2004) 1.53
Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol (2007) 1.53
Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 1.51
Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. J Virol (2007) 1.50
Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer (2007) 1.50
Viral RNA patterns and high viral load reliably define oropharynx carcinomas with active HPV16 involvement. Cancer Res (2012) 1.49
High-throughput detection and multiplex identification of cell contaminations. Nucleic Acids Res (2009) 1.49
Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study. Am J Epidemiol (2013) 1.48
The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood (2008) 1.48
Insulators, not Polycomb response elements, are required for long-range interactions between Polycomb targets in Drosophila melanogaster. Mol Cell Biol (2010) 1.47
High-throughput SNP-based authentication of human cell lines. Int J Cancer (2012) 1.46
Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev (2007) 1.45
Reelin deficiency and displacement of mature neurons, but not neurogenesis, underlie the formation of granule cell dispersion in the epileptic hippocampus. J Neurosci (2006) 1.45
In vitro versus in vivo cellulose microfibrils from plant primary wall synthases: structural differences. J Biol Chem (2002) 1.44
Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog (2008) 1.44
Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer (2013) 1.42
Interactions between papillomavirus L1 and L2 capsid proteins. J Virol (2003) 1.41
Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord (2003) 1.41
Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer (2014) 1.40
Human papillomavirus seropositivity and risks of head and neck cancer. Int J Cancer (2007) 1.39
Recognition of 2'-O-methylated 3'-end of piRNA by the PAZ domain of a Piwi protein. Structure (2011) 1.37
KI, WU and Merkel cell polyomaviruses: a new era for human polyomavirus research. Semin Cancer Biol (2009) 1.37
Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol (2008) 1.35
The significance of direct sunlight and polarized skylight in the ant's celestial system of navigation. Proc Natl Acad Sci U S A (2006) 1.35
Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine (2003) 1.34
Cyclophilins facilitate dissociation of the human papillomavirus type 16 capsid protein L1 from the L2/DNA complex following virus entry. J Virol (2012) 1.34
Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol (2013) 1.34
Helicobacter pylori infection and gastric cancer risk: evaluation of 15 H. pylori proteins determined by novel multiplex serology. Cancer Res (2009) 1.33
Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology (2007) 1.32
Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr Opin Biotechnol (2004) 1.32
Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J Virol (2007) 1.30
Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer Res (2010) 1.30
Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study. Cancer Epidemiol Biomarkers Prev (2008) 1.29
Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study. J Natl Cancer Inst (2013) 1.29
Helicobacter pylori multiplex serology. Helicobacter (2009) 1.29
Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin Cancer Res (2009) 1.28
Nuclear translocation of papillomavirus minor capsid protein L2 requires Hsc70. J Virol (2004) 1.27
Complex etiology underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol: a case for multifactor disease. J Oncol (2012) 1.27